SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or "Calidi"), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, announced a 2millionstrategicinvestmentbyDr.RonaldRigorintoitsnewsubsidiary,NovaCell,Inc.("NovaCell"),toadvanceCalidi′sAdultAdiposeAllogeneic(AAA)stemcellinnovativeprograms.DrRigoralsoinvestedanadditional1 million into Calidi to further its oncology pipeline of a ...